Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...
13d
Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish
Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart ...
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Stocktwits on MSN
Pfizer reports positive weight-loss trial results, strong Q4 – so why is PFE stock falling?
Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes. ・The company plans to launch more than 20 trials in 2026, ...
Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.
Sciwind said the agreement marks “an important first step to advance Pfizer's global strategy in the metabolic field in China,” according ...
10h
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ...
Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results